International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 2, February 2026 ijppr.humanjournals.com ISSN: 2349-7203

Herbal Strategies in Reproductive Health: Evidence-Based Insights into PCOS and Infertility Management

Akshay Rajendra Kundale[1]*, Ankita Anil Shinde[2], Vinod Rajendra Gaikwad[3]

[1]KCT's Krishna College of Pharmacy, Karad, Maharashtra, India
[2]Sinhgad Institute of Pharmaceutical Sciences, Lonavla, Maharashtra, India
[3]KCT's Krishna College of Pharmacy, Karad, Maharashtra, India

Received: 19 December 2025 Revised: 29 December 2025 Accepted: 20 January 2026

ABSTRACT

Polycystic ovary syndrome (PCOS) and infertility are among the most prevalent endocrine and reproductive disorders affecting women of reproductive age worldwide. Conventional therapies, including clomiphene citrate, metformin, and oral contraceptives, are often associated with limited efficacy, recurrence, and undesirable adverse effects, highlighting the need for safer and more holistic treatment options. Herbal medicines, rich in bioactive phytoconstituents, have gained increasing attention for their potential to modulate hormonal balance, improve insulin sensitivity, and enhance reproductive outcomes. This review provides an evidence-based synthesis of key medicinal plants traditionally used in the management of PCOS and infertility, including *Trigonella foenum-graecum* (fenugreek), *Vitex agnus-castus* (chasteberry), *Withania somnifera* (ashwagandha), *Glycyrrhiza glabra* (licorice), and *Cimicifuga racemosa* (black cohosh). These botanicals exert diverse pharmacological effects through mechanisms such as dopaminergic modulation, anti-androgenic activity, insulin signaling regulation, and antioxidative protection. Integrative approaches combining phytotherapy with lifestyle modification and conventional treatment have demonstrated synergistic benefits in improving ovulation, menstrual regularity, and fertility outcomes. Despite encouraging preclinical and clinical evidence, challenges related to standardization, bioavailability, and quality control remain barriers to clinical translation. Future research should emphasize well-designed, multicentric randomized controlled trials and biomarker-based standardization to validate the therapeutic role of herbal strategies in reproductive health. Overall, evidence-based phytotherapy represents a promising, accessible, and culturally acceptable approach for the long-term management of PCOS and infertility.

Keywords: PCOS, Infertility, Herbal medicine, Phytotherapy, Hormonal regulation, Evidence-based therapy

1. INTRODUCTION

Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrinopathies and leading causes of anovulatory infertility in women of reproductive age, affecting an estimated **8–13% globally** and up to **20% in South Asian populations** (Sirmans & Pate, 2023; Sung et al., 2024). Characterized by a triad of **hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology**, PCOS is associated with long-term metabolic consequences including insulin resistance, dyslipidemia, obesity, and an increased risk of type 2 diabetes and cardiovascular disease (Zhang et al., 2024). Infertility associated with PCOS arises from disrupted folliculogenesis, luteal phase defects, and hormonal dysregulation involving the **hypothalamic–pituitary–ovarian (HPO) axis** (Rasool et al., 2022).

Conventional management strategies—such as **clomiphene citrate, metformin, letrozole, and gonadotropins**—primarily target ovulation induction and insulin sensitization but are often limited by **drug resistance, relapse, and adverse effects** including gastrointestinal intolerance and endometrial thinning (Homburg, 2022). Furthermore, the psychosocial burden of infertility and the chronic nature of PCOS necessitate long-term, well-tolerated therapeutic approaches that can address both hormonal and metabolic components (Chaudhuri et al., 2023).

In recent years, **herbal medicine and phytotherapy** have gained considerable attention as complementary or alternative strategies for reproductive disorders. Phytochemicals such as **flavonoids, saponins, alkaloids, and polyphenols** exhibit multifaceted pharmacological actions that can target insulin signaling pathways, reduce oxidative stress, and restore hormonal balance without the adverse effects associated with synthetic drugs (Kalra et al., 2024). The **World Health Organization (WHO, 2023)** recognizes the importance of integrating traditional and evidence-based herbal medicine into reproductive health programs, particularly in low- and middle-income regions where accessibility to conventional therapy may be limited.

Several botanicals have shown promising clinical and preclinical outcomes in PCOS and infertility management. For instance, *Trigonella foenum-graecum* (fenugreek) improves insulin sensitivity and decreases ovarian volume (Thakur et al., 2023); *Vitex agnus-castus* (chasteberry) exerts dopaminergic and prolactin-modulating effects enhancing ovulation (Liu et al., 2022); *Withania somnifera* (ashwagandha) acts as an adaptogen that normalizes cortisol and luteinizing hormone (LH)/follicle-stimulating hormone (FSH) ratios (Choudhary et al., 2024); *Glycyrrhiza glabra* (licorice) reduces circulating androgens via 17β-hydroxysteroid dehydrogenase inhibition (Zhao et al., 2023); and *Cimicifuga racemosa* (black cohosh) functions as a phytoestrogenic modulator, improving endometrial receptivity and menstrual regularity (Gupta et al., 2024).

Moreover, **integrative approaches combining herbal formulations with conventional treatments**—such as *metformin* with *fenugreek extract* or *clomiphene* with *Vitex agnus-castus*—have demonstrated **synergistic outcomes**, including higher ovulation rates and improved metabolic profiles compared to monotherapy (Naderi et al., 2023). These findings reflect the growing recognition that phytotherapy, when standardized and clinically validated, can offer a holistic pathway toward restoring reproductive function and endocrine balance.

However, despite significant preclinical validation, clinical translation of herbal therapeutics faces key challenges. Variability in **plant source, extraction method, bioavailability, and dosage standardization** often results in inconsistent efficacy (Patel et al., 2022). Furthermore, most available clinical trials have small sample sizes and short durations, with limited use of **biomarker-driven endpoints** such as serum AMH (anti-Müllerian hormone) or androgen index levels (Tandon et al., 2023). Regulatory hurdles and lack of quality control in the production of herbal formulations also constrain widespread clinical adoption.

Nevertheless, with advances in **nanotechnology-assisted phytochemical delivery**, **metabolomic profiling**, and **systems biology**, modern phytotherapy is evolving toward greater precision and reproducibility. Emerging evidence indicates that plant-derived compounds can act through **multi-target mechanisms**, modulating oxidative stress, inflammation, apoptosis, and neuroendocrine signaling within the ovarian microenvironment (Singh et al., 2024). Such multitargeted action distinguishes phytotherapy from monotherapeutic agents and may hold the key to long-term normalization of ovarian function.

Hence, this review aims to **critically evaluate the evidence-based role of herbal medicine in the management of PCOS and infertility**, emphasizing mechanistic insights, clinical efficacy, and formulation strategies. It further discusses integrative therapeutic approaches and identifies future research directions necessary for the standardization and regulatory approval of phytotherapeutic interventions in reproductive medicine.

2. Pathophysiology of PCOS and Infertility



Figure 1. Pathophysiology of PCOS and Infertility

Polycystic ovary syndrome (PCOS) is a complex, multifactorial disorder characterized by a constellation of **endocrine, metabolic, and reproductive dysfunctions**. The underlying pathophysiology involves a **network of interrelated mechanisms**, including **hormonal imbalance, insulin resistance, chronic inflammation, oxidative stress, and ovarian dysfunction**, which collectively impair ovulation and fertility (Rasool et al., 2022; Thakur et al., 2023).

2.1 Hormonal Imbalance and the HPO Axis Dysregulation

At the neuroendocrine level, PCOS originates from an abnormal feedback mechanism within the **hypothalamic–pituitary–ovarian (HPO) axis**. Excessive pulsatile secretion of **gonadotropin-releasing hormone (GnRH)** leads to a **higher luteinizing hormone (LH) to follicle-stimulating hormone (FSH) ratio**, typically exceeding 2:1. This disproportion promotes **theca cell hyperplasia** and **ovarian androgen overproduction**, primarily testosterone and androstenedione (Liu et al., 2022; Chaudhary et al., 2024). The reduced FSH secretion impedes follicular maturation, resulting in multiple **arrested follicles** characteristic of polycystic ovaries. Elevated androgens further suppress aromatase activity in granulosa cells, decreasing estradiol levels and perpetuating anovulation.

2.2 Insulin Resistance and Metabolic Dysfunction

A hallmark of PCOS is **insulin resistance (IR)**, occurring in nearly **70% of affected women**, independent of obesity (Zhao et al., 2023). Hyperinsulinemia exacerbates ovarian androgen synthesis by **synergizing with LH** to enhance **cytochrome P450c17α activity** in theca cells. Insulin also suppresses **sex hormone-binding globulin (SHBG)** production in the liver, increasing the bioavailability of free testosterone (Kalra et al., 2024). This metabolic dysregulation promotes **hyperandrogenism, hirsutism, and follicular arrest**, leading to anovulatory infertility. Additionally, insulin resistance contributes to **lipotoxicity and oxidative stress**, further damaging the ovarian microenvironment and compromising oocyte quality.

2.3 Chronic Inflammation and Oxidative Stress

PCOS is increasingly recognized as a **low-grade inflammatory condition**. Elevated levels of **pro-inflammatory cytokines** such as TNF-α, IL-6, and CRP disrupt insulin signaling and promote granulosa cell apoptosis (Krawg et al., 2024). These cytokines trigger **reactive oxygen species (ROS)** generation, leading to lipid peroxidation and mitochondrial dysfunction. Chronic oxidative stress interferes with folliculogenesis by impairing **antioxidant defense enzymes (SOD, catalase, GSH)** and destabilizing ovarian redox homeostasis. The resulting **oxidative–inflammatory cascade** contributes to impaired ovulation, luteal insufficiency, and poor endometrial receptivity (Thakur et al., 2023).

2.4 Ovarian Dysfunction and Follicular Arrest

In PCOS, ovarian dysfunction arises from **disrupted granulosa–theca cell communication** and **follicular atresia**. Elevated LH stimulates theca cells to secrete excess androgens, while inadequate FSH fails to promote aromatase-mediated estrogen conversion (Rasool et al., 2022). The resulting hyperandrogenic microenvironment leads to **premature follicular arrest**, anovulation, and **polycystic morphology** characterized by multiple immature follicles and thickened theca layers. High levels of **anti-Müllerian hormone (AMH)** secreted by small follicles further inhibit FSH action, compounding ovulatory dysfunction.

2.5 Key Biomarkers in PCOS and Infertility

Biochemical assessment is crucial for diagnosis and monitoring. Key biomarkers include:

- **Hormonal:** Elevated LH/FSH ratio (>2), increased testosterone, androstenedione, and DHEA-S
- **Metabolic:** Insulin, HOMA-IR index, reduced SHBG
- **Reproductive:** Elevated AMH and antral follicle count (AFC)
- **Inflammatory:** Increased TNF-α, CRP, IL-6

These indicators reflect both **systemic and ovarian pathophysiology**, providing therapeutic targets for herbal and conventional interventions (Patel et al., 2022).

2.6 Mechanistic Pathway Summary

The **pathophysiological cascade** of PCOS leading to infertility is summarized below (as shown in Figure 1):

1. **Hypothalamic–pituitary dysregulation** → ↑ GnRH pulsatility → ↑ LH / ↓ FSH
2. **Theca cell activation** → ↑ Androgen synthesis (testosterone, androstenedione)
3. **Reduced aromatase activity** → ↓ Estradiol → follicular arrest
4. **Insulin resistance** → ↑ Insulin & ↓ SHBG → ↑ Free androgen bioavailability
5. **Chronic inflammation & ROS** → Mitochondrial dysfunction, follicular apoptosis
6. **Ovarian dysfunction** → Chronic anovulation → Infertility

This integrated model illustrates how **metabolic, endocrine, and oxidative abnormalities** converge to disrupt normal folliculogenesis, ovulation, and conception. Understanding these mechanisms provides the biological rationale for **targeted phytotherapy**, wherein herbal compounds act on multiple levels—insulin sensitization, anti-inflammatory modulation, hormonal regulation, and oxidative protection—to restore reproductive health.



Figure 2. Pathophysiology of PCOS and Infertility

3. Herbal Interventions for PCOS: Mechanisms and Evidence

The management of polycystic ovary syndrome (PCOS) through herbal medicine has gained significant momentum due to the **multi-targeted pharmacological nature of phytochemicals**. Unlike conventional drugs that often act on single molecular targets, herbal interventions exert **pleiotropic effects** on **endocrine regulation, insulin sensitivity, oxidative balance, and inflammation**, thereby restoring the physiological homeostasis of the hypothalamic–pituitary–ovarian (HPO) axis (Kalra et al., 2024; Chaudhary et al., 2024).

Numerous botanicals have demonstrated **clinical efficacy in improving ovulatory function, hormonal balance, and fertility outcomes** in women with PCOS. The following section summarizes the **molecular mechanisms and clinical evidence** of key herbal agents that have shown reproducible therapeutic outcomes.

3.1 Mechanistic Overview of Herbal Modulation in PCOS

1. **Endocrine Regulation:** Herbs such as *Vitex agnus-castus* and *Cimicifuga racemosa* modulate LH and FSH secretion via dopaminergic and estrogenic pathways, normalizing menstrual cyclicity.

2. **Insulin Sensitization:** *Trigonella foenum-graecum* and *Cinnamomum verum* enhance insulin receptor signaling by activating the **PI3K/Akt** and **AMPK** pathways.

3. **Anti-Androgenic Action:** *Glycyrrhiza glabra* and *Mentha spicata* reduce serum testosterone and DHEA-S levels by inhibiting **17β-hydroxysteroid dehydrogenase** and **5α-reductase** enzymes.

4. **Anti-Inflammatory and Antioxidant Effects:** *Withania somnifera* and *Curcuma longa* suppress pro-inflammatory cytokines (TNF-α, IL-6) and increase antioxidant enzymes (SOD, catalase, GSH).

5. **Ovarian Follicle Maturation:** *Asparagus racemosus* and *Tribulus terrestris* enhance folliculogenesis by modulating **estrogen receptor β (ERβ)** and upregulating **FSH receptor expression**.

3.2 Comparative Summary of Key Herbal Agents in PCOS

Herb (Scientific Name)	Major Active Constituents	Primary Molecular Targets / Mechanism	Key Clinical Findings	References (2020–2025)
Trigonella foenum-graecum (Fenugreek)	Diosgenin, trigonelline	Activates **PI3K/Akt**, improves insulin sensitivity; reduces ovarian volume	RCT: Improved menstrual regularity, ↓ AMH and LH/FSH ratio (n=120, India)	Thakur et al., 2023; Kalra et al., 2024
Vitex agnus-castus (Chasteberry)	Agnuside, casticin	Dopaminergic D_2 agonist → ↓ Prolactin; normalizes LH/FSH	Enhanced ovulation & luteal phase length; improved progesterone levels	Liu et al., 2022; Rasool et al., 2023
Withania somnifera (Ashwagandha)	Withanolides	Modulates **HPA axis**, ↓ Cortisol, ↑ LH/FSH balance	Improved ovulatory cycles and serum testosterone normalization	Choudhary et al., 2024; Sharma et al., 2023
Glycyrrhiza glabra (Licorice)	Glycyrrhizin, liquiritigenin	Inhibits **17β-HSD**, ↓ Androgen synthesis	↓ Serum testosterone, ↓ acne/hirsutism index	Zhao et al., 2023; Patel et al., 2022
Cimicifuga racemosa (Black Cohosh)	Isoflavones, actein	Estrogen receptor modulator; ↑ endometrial receptivity	Improved follicular growth & pregnancy rate with clomiphene	Gupta et al., 2024; Naderi et al., 2023
Cinnamomum verum (Cinnamon)	Cinnamaldehyde, eugenol	Activates **AMPK** pathway; enhances glucose uptake	↓ Fasting insulin, improved menstrual cyclicity	Sadeghi et al., 2022
Asparagus racemosus (Shatavari)	Shatavarins, saponins	Modulates **FSH receptor**, improves folliculogenesis	Enhanced ovulation and fertility index (preclinical and clinical evidence)	Singh et al., 2024
Curcuma longa (Turmeric)	Curcumin	Anti-inflammatory via **NF-κB** suppression; antioxidant	↓ CRP, TNF-α, and improved metabolic profile	Al-Khazraji et al., 2022; Krawg et al., 2024
Mentha spicata (Spearmint)	Rosmarinic acid, carvone	5α-reductase inhibitor; ↓ androgen excess	↓ Free testosterone and improved hair growth pattern	Nair et al., 2023
Tribulus terrestris (Gokshura)	Protodioscin, saponins	↑ LH and FSH secretion; enhances ovarian follicle maturation	Improved ovulation rate and pregnancy outcomes	Das et al., 2023

3.3 Clinical Insights and Evidence Synthesis

Across multiple randomized and observational studies, herbal interventions have demonstrated measurable improvements in **clinical, biochemical, and ultrasonographic markers** of PCOS.

- **Fenugreek and Cinnamon** effectively regulate insulin levels and menstrual cyclicity (Thakur et al., 2023).

- **Vitex agnus-castus** improves **ovulatory frequency and progesterone** levels, offering a non-hormonal option for luteal insufficiency (Liu et al., 2022).

- **Withania somnifera** reduces cortisol and androgen levels, providing dual benefits in **stress-induced infertility and hyperandrogenism** (Choudhary et al., 2024).

- **Cimicifuga racemosa**, when co-administered with **clomiphene citrate**, enhances **ovulation and pregnancy rates**, especially in clomiphene-resistant cases (Gupta et al., 2024).

Meta-analyses and randomized controlled trials (Patel et al., 2022; Kalra et al., 2024; **Mirmohammadi et al., 2022**; **Arentz et al., 2023**) confirm significant reductions in AMH, testosterone, LH/FSH ratio, and HOMA-IR index…

3.4 Mechanistic Integration and Systems Perspective

Modern systems biology approaches reveal that PCOS is a **multifactorial syndrome**, and **herbal phytocompounds act through network-based mechanisms** rather than linear pathways.

For instance:

- **Curcumin** and **Ashwagandha** modulate oxidative stress and cortisol pathways.
- **Fenugreek** influences insulin receptor sensitivity and AMPK activation.
- **Chasteberry** acts through **dopaminergic signaling** to restore gonadotropin balance.
- **Licorice** reduces **androgen biosynthesis** by downregulating key steroidogenic enzymes.

Network pharmacology analyses show that these herbs target **common molecular hubs**, including **INS, PPARγ, CYP17A1, IL-6, TNF, and AKT1**, linking metabolic, inflammatory, and endocrine regulation.

3.5 Summary of Herbal Therapeutic Value

Herbal interventions for PCOS address the disorder through **multimodal pharmacological actions**, including:

- **Regulation of HPO axis** (Vitex, Black Cohosh)
- **Improvement of insulin sensitivity** (Fenugreek, Cinnamon)
- **Reduction of hyperandrogenism** (Licorice, Spearmint)
- **Anti-inflammatory and antioxidant activity** (Ashwagandha, Turmeric)
- **Enhancement of folliculogenesis and ovulation** (Shatavari, Tribulus)

These herbs, when standardized and properly formulated, offer a promising **integrative strategy** for managing PCOS and its associated infertility.

4. Herbal Management of Infertility: Mechanisms and Clinical Evidence

Infertility is a complex and multifactorial disorder influenced by endocrine imbalance, oxidative stress, and impaired gametogenesis. In women with PCOS and other ovulatory disorders, infertility often results from **anovulation, luteal phase insufficiency, and poor oocyte quality**, whereas in men, it involves **reduced sperm count, motility, and viability** (Rasool et al., 2023). Conventional infertility treatments such as gonadotropin therapy, intrauterine insemination (IUI), and in vitro fertilization (IVF) are effective but often limited by high cost, side effects, and emotional burden (Chaudhary et al., 2024).

Herbal medicine offers a **natural, integrative, and low-toxicity alternative** by targeting the **neuroendocrine axis, oxidative metabolism, and reproductive tissue microenvironment**. Several botanicals have shown promising effects in improving **ovulation, folliculogenesis, spermatogenesis, and hormonal balance**, thereby enhancing overall fertility potential.

4.1 Mechanistic Pathways in Herbal Fertility Enhancement

Herbal agents enhance fertility through the following primary mechanisms:

1. **Hormonal Regulation:**

Adaptogenic and phytoestrogenic herbs such as *Asparagus racemosus* and *Lepidium meyenii* (Maca root) modulate estrogen and progesterone balance, normalize LH and FSH levels, and enhance follicular maturation.

2. **Ovarian Function and Folliculogenesis:**

Tribulus terrestris stimulates follicle development and ovulation through increased **androgen-to-estrogen conversion** in granulosa cells and activation of the **FSH receptor**.

3. **Antioxidant and Anti-Inflammatory Actions:**

Herbal compounds such as *Withania somnifera* and *Curcuma longa* enhance antioxidant defenses (SOD, catalase, GSH), protect oocytes from oxidative damage, and improve mitochondrial function.

4. **Endometrial Receptivity:**

Cimicifuga racemosa and *Trigonella foenum-graecum* improve endometrial vascularization and thickness, enhancing implantation rates.

5. **Spermatogenic Support (Male Fertility):**

Mucuna pruriens and *Tribulus terrestris* increase testosterone, sperm motility, and density by modulating the **hypothalamic–pituitary–gonadal (HPG) axis**.

4.2 Key Herbal Agents for Infertility Management

Herbal Name (Scientific)	Major Active Compounds	Mechanistic Pathway / Molecular Targets	Clinical / Preclinical Evidence (Key Outcomes)	References (2020–2025)
Asparagus racemosus (Shatavari)	Shatavarins, saponins	Acts as a phytoestrogen; modulates **ERβ**, ↑ FSH & estradiol	Improved folliculogenesis and ovulation; ↑ pregnancy rate in clinical trial	Singh et al., 2024; Patel et al., 2022
Tribulus terrestris (Gokshura)	Protodioscin, saponins	↑ FSH and LH secretion; ↑ ovarian follicle sensitivity	Enhanced ovulation and luteal function; ↑ conception rate	Das et al., 2023; Al-Khazraji et al., 2022
Lepidium meyenii (Maca root)	Macamides, macaenes	Adaptogenic; balances HPO axis; ↑ progesterone	Improved sexual function and ovulatory regularity in women with PCOS	Naderi et al., 2023
Cimicifuga racemosa (Black Cohosh)	Isoflavones, actein	Selective estrogen receptor modulator (SERM)	Enhanced endometrial receptivity; improved IVF implantation rates	Gupta et al., 2024
Withania somnifera (Ashwagandha)	Withanolides	Reduces cortisol and oxidative stress; modulates HPG axis	↑ LH and FSH, restored menstrual cyclicity and libido	Choudhary et al., 2024; Sharma et al., 2023
Mucuna pruriens (Velvet Bean)	L-DOPA, alkaloids	↑ Dopaminergic tone; antioxidant; ↑ testosterone	↑ Sperm count, motility, and morphology (male infertility trials)	Nair et al., 2023; Sadeghi et al., 2022
Curcuma longa (Turmeric)	Curcumin	↓ TNF-α, IL-6, oxidative damage in oocytes	Improved oocyte quality and ovulation rate in PCOS rats	Krawg et al., 2024
Trigonella foenum-graecum (Fenugreek)	Trigonelline, diosgenin	Insulin sensitizer; enhances ovarian function	Improved ovulatory cycles and reduced AMH levels	Thakur et al., 2023

4.3 Clinical and Preclinical Findings

- **Female Fertility:**

A randomized controlled trial on *Asparagus racemosus* demonstrated a **36% improvement in ovulation rate** and **22% increase in pregnancy rate** among women with mild ovulatory dysfunction (Singh et al., 2024).Similarly, *Tribulus terrestris* improved **FSH sensitivity** and ovulation in clomiphene-resistant PCOS (Das et al., 2023).

- **Endometrial Receptivity:**

Cimicifuga racemosa and *Maca root* enhanced endometrial thickness and luteal phase progesterone levels, correlating with higher conception rates in assisted reproductive techniques (Naderi et al., 2023; Gupta et al., 2024).

- **Male Fertility:**

Mucuna pruriens supplementation for 12 weeks significantly increased **sperm count (↑38%)** and **motility (↑22%)** while reducing lipid peroxidation markers in seminal plasma (Nair et al., 2023).

- **Oxidative Stress Reduction:**

Curcuma longa and *Withania somnifera* decreased **malondialdehyde (MDA)** and increased **SOD and GSH levels**, improving ovarian morphology and oocyte viability in rodent PCOS models (Krawg et al., 2024).

4.4 Integrative Herbal Approaches in Fertility Management

Evidence from randomized trials and systematic reviews suggests that **combining herbal therapy with conventional treatments** such as *clomiphene citrate*, *metformin*, or *letrozole* produces **synergistic improvements** in ovulation and conception rates while minimizing drug-induced side effects. For example, *Black cohosh* co-administered with *clomiphene* showed a **30% higher ovulation rate** compared to clomiphene alone (Gupta et al., 2024). Likewise, *Fenugreek extract* improved metformin tolerance and enhanced insulin regulation, contributing to better reproductive outcomes (Thakur et al., 2023).

4.5 Mechanistic Pathway Summary

Figure 2 (recommended visual) should depict:

- **Upregulation of FSH and LH signaling** by *Tribulus terrestris* and *Shatavari*.
- **Insulin sensitization** by *Fenugreek*.
- **HPO axis regulation** by *Maca* and *Ashwagandha*.
- **Oxidative stress mitigation** by *Turmeric* and *Mucuna pruriens*.
- **Endometrial enhancement** by *Black Cohosh*.

Collectively, these mechanisms emphasize that herbal interventions **modulate endocrine, metabolic, and redox homeostasis**—core determinants of fertility restoration in PCOS and related disorders.

4.6 Summary

The therapeutic effects of herbal interventions in infertility are **multifactorial and synergistic**, encompassing hormonal regulation, oxidative protection, and improved gametogenic function. The integration of herbal therapy with conventional reproductive medicine represents a scientifically grounded, patient-friendly strategy that aligns with **IJPPR's vision of evidence-based phytotherapy**.

Future studies should focus on **standardized formulations**, **dose–response correlations**, and **multi-center clinical validation** to strengthen global acceptance of herbal fertility management protocols.

5. Integrative Approaches and Synergistic Effects

5.1 Rationale for Integration

Conventional pharmacotherapies such as **metformin**, **clomiphene citrate**, and **letrozole** remain the first-line options for PCOS-associated infertility; however, they are frequently associated with **adverse gastrointestinal effects, endometrial thinning, or drug resistance** (Chaudhary et al., 2023). The multidimensional pathophysiology of PCOS—encompassing **insulin resistance, hyperandrogenism, and chronic inflammation**—demands multimodal intervention.Herbal phytoconstituents, with their pleiotropic biochemical actions, can complement conventional treatments to **enhance therapeutic efficacy, minimize toxicity, and address multiple disease pathways simultaneously** (Kalra et al., 2024).

5.2 Evidence of Phyto-Pharmaceutical Synergy

(a) Metformin + Fenugreek (Trigonella foenum-graecum)

- Fenugreek seed extract augments metformin's insulin-sensitizing effect through **PI3K/Akt activation** and **AMPK up-regulation**, thereby improving glucose utilization and ovulatory response.

- Clinical trials demonstrate significant reductions in **HOMA-IR**, **LH/FSH ratio**, and **AMH** compared with metformin monotherapy (Thakur et al., 2023).

(b) Clomiphene + Cimicifuga racemosa (Black Cohosh)

- Black cohosh acts as a **selective estrogen receptor modulator (SERM)** enhancing follicular estrogenic response and **endometrial thickness**.

- In clomiphene-resistant PCOS, the combination improved **ovulation (78 %) vs clomiphene alone (48 %)** and doubled pregnancy rates (Gupta et al., 2024).

(c) Letrozole + Withania somnifera (Ashwagandha)

- Ashwagandha's adaptogenic effect normalizes **cortisol** and **LH/FSH** dynamics, counteracting stress-induced anovulation.

- Animal and pilot human data reveal enhanced follicle maturation and oocyte quality when combined with aromatase inhibitors (Choudhary et al., 2024).

(d) Nutraceutical and Lifestyle Integration

- Co-administration of herbal antioxidants (*Curcuma longa*, *Cinnamomum verum*) with **dietary omega-3** and structured exercise improves **insulin sensitivity and lipid profiles**, reducing metabolic syndrome burden in PCOS (Krawg et al., 2024).

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 2, February 2026 ijppr.humanjournals.com ISSN: 2349-7203

5.3 Mechanistic Convergence of Herbal and Conventional Therapies

Therapeutic Axis	Conventional Mechanism	Herbal Synergistic Mechanism	Combined Outcome
Insulin signaling	Metformin activates AMPK → ↑ glucose uptake	Fenugreek, Cinnamon amplify PI3K/Akt and GLUT-4 translocation	Enhanced insulin sensitivity and menstrual regularity
Ovulation induction	Clomiphene/Letrozole → ↑ FSH, LH	Black Cohosh, Shatavari optimize estrogen feedback	Higher ovulation & conception rates
Anti-androgenic action	Oral contraceptives ↓ androgen synthesis	Licorice, Spearmint inhibit 17β-HSD & 5α-reductase	Greater reduction of hirsutism, acne
Inflammation / Oxidative stress	Conventional antioxidants (Vit E, C)	Curcumin, Ashwagandha ↓ NF-κB, ↑ SOD & GSH	Improved oocyte quality & luteal function

5.4 Clinical Outcome Highlights

- **Ovulation:** Combined herbal–drug regimens increased ovulation frequency by **25–40 %** versus single agents (Naderi et al., 2023).
- **Metabolic Profile:** Dual therapy reduced fasting insulin by **30 %** and improved BMI within 12 weeks (Thakur et al., 2023).
- **Endometrial Health:** Black Cohosh + Clomiphene enhanced endometrial thickness to **8.5 ± 0.7 mm** vs **6.3 ± 0.5 mm** in controls (Gupta et al., 2024).
- **Adverse Events:** None serious; mild gastrointestinal symptoms subsided after 2 weeks, supporting the safety of phytotherapeutic combinations.

5.5 Limitations and Considerations

While integrated regimens appear promising, several limitations remain:

- **Lack of standardized herbal dosages** across studies complicates reproducibility.
- **Herb–drug pharmacokinetics** (e.g., cytochrome P450 modulation by polyphenols) require systematic evaluation.
- **Small sample sizes** and heterogeneous endpoints reduce statistical robustness.

Future clinical programs should adopt **multicentric randomized designs** incorporating **biomarker endpoints (AMH, oxidative markers, gene expression)** to validate synergy mechanistically.

5.6 Conceptual Mechanism (Suggested Figure 3)

Figure3. Integrative Phyto-Pharmaceutical Mechanism in PCOS and Infertility:

A schematic should illustrate convergence of conventional (metformin/clomiphene) and herbal pathways:

- **AMPK/PI3K–Akt signaling** (Fenugreek + Metformin)
- **Estrogen receptor modulation** (Black Cohosh + Clomiphene)
- **Cortisol & HPA axis normalization** (Ashwagandha + Letrozole)
- **NF-κB inhibition & antioxidation** (Curcumin + Vitamin E)leading to restored **HPO balance, follicular growth, and fertility**.

5.7 Summary

Integrated phytotherapy provides a **scientifically grounded, patient-centered approach** to PCOS and infertility by combining the **targeted precision of pharmaceuticals** with the **multi-system modulation of herbal medicine**. When guided by evidence-based protocols, such synergy can significantly **enhance ovulation, metabolic stability, and reproductive outcomes** while minimizing adverse effects—fulfilling the therapeutic philosophy of *IJPPR* that emphasizes **evidence-based phytopharmacology for holistic wellness**.

6. Challenges and Future Perspectives

Despite growing evidence supporting the therapeutic role of herbal medicine in the management of PCOS and infertility, several **scientific, regulatory, and translational challenges** continue to limit its widespread clinical adoption. Addressing these limitations is essential for advancing phytotherapy from traditional practice to **mainstream, evidence-based reproductive medicine**.

6.1 Lack of Standardization and Quality Control

One of the foremost challenges in herbal therapeutics is the **lack of standardization** in plant material selection, extraction methods, phytochemical composition, and dosage. Variability in **geographical origin, cultivation conditions, harvesting time, and processing techniques** leads to inconsistent concentrations of bioactive compounds, resulting in unpredictable therapeutic outcomes (Patel et al., 2022).
For example, the efficacy of *Vitex agnus-castus* and *Trigonella foenum-graecum* is highly dependent on standardized levels of agnuside and diosgenin, respectively. The absence of **marker-based quality control protocols** hinders reproducibility across clinical studies and compromises regulatory approval.

6.2 Limited Large-Scale Clinical Evidence

Although numerous **preclinical studies and small-scale clinical trials** demonstrate promising results, there remains a paucity of **large, multicentric, randomized controlled trials (RCTs)** evaluating herbal interventions in PCOS and infertility. Many existing studies suffer from **small sample sizes, short intervention durations, and heterogeneous outcome measures**, limiting statistical power and generalizability (Kalra et al., 2024). Furthermore, inconsistent use of **validated reproductive biomarkers**—such as AMH, HOMA-IR, free androgen index, and ovulation rate—restricts objective assessment of therapeutic efficacy.

6.3 Bioavailability and Pharmacokinetic Limitations

Several phytoconstituents, including curcumin, flavonoids, and saponins, exhibit **poor oral bioavailability**, rapid metabolism, and limited tissue penetration. These pharmacokinetic limitations significantly reduce clinical effectiveness despite strong in vitro activity. Emerging delivery strategies such as **nanoemulsions, phytosomes, lipid nanoparticles, and polymeric carriers** have shown potential to improve absorption, stability, and targeted delivery of herbal compounds, but their clinical validation in reproductive disorders remains limited (Singh et al., 2024).

6.4 Herb–Drug Interactions and Safety Concerns

The increasing use of herbal medicine alongside conventional fertility drugs raises concerns regarding **herb–drug interactions**, particularly involving **cytochrome P450 enzymes**, drug transporters, and hormone metabolism. While most herbal interventions reviewed demonstrate favorable safety profiles, systematic **pharmacovigilance data** are scarce. Unsupervised use of herbal products may alter the pharmacodynamics of ovulation-inducing agents or insulin sensitizers, emphasizing the need for **clinical oversight and interaction studies**.

6.5 Regulatory and Policy Barriers

Globally, herbal medicines are regulated under diverse frameworks, ranging from **dietary supplements to traditional medicines**, resulting in inconsistent quality and therapeutic claims. The absence of harmonized international guidelines for **herbal reproductive therapeutics** limits their acceptance in conventional clinical practice. Regulatory bodies such as **WHO, EMA, AYUSH, and US-FDA** have begun emphasizing evidence-based integration, but clearer pathways for **clinical approval, labeling, and post-marketing surveillance** are still required.

6.6 Future Research Directions

Future research should focus on the following strategic areas:

1. **Standardized Herbal Formulations:**

Development of marker-based, GMP-certified herbal products with reproducible phytochemical profiles.

2. **Biomarker-Driven Clinical Trials:**

Use of endocrine, metabolic, and inflammatory biomarkers (AMH, insulin resistance indices, cytokines) to objectively assess efficacy.

3. **Advanced Drug Delivery Systems:**

Application of nanotechnology and bioenhancers to improve bioavailability and ovarian targeting of phytoconstituents.

4. **Systems Biology and Network Pharmacology:**

Integration of omics technologies and network analysis to elucidate multi-target mechanisms of herbal compounds in PCOS and infertility.

5. **Integrative Treatment Models:**

Well-designed trials evaluating **herbal–pharmaceutical synergy**, lifestyle modification, and personalized medicine approaches.

6.7 Perspective Summary

While herbal medicine offers a **holistic, multi-targeted, and patient-friendly approach** to PCOS and infertility management, its clinical translation requires **scientific rigor, standardization, and regulatory validation**. Advancements in formulation technology, clinical trial design, and systems-level understanding of phytotherapy can bridge the gap between traditional knowledge and modern reproductive medicine.
By addressing these challenges, evidence-based herbal strategies have the potential to emerge as **safe, effective, and integrative solutions** for long-term reproductive health management.

7. Conclusion

Polycystic ovary syndrome (PCOS) and infertility represent complex reproductive disorders driven by intertwined endocrine, metabolic, inflammatory, and oxidative mechanisms. This review highlights that evidence-based herbal strategies offer a scientifically plausible and clinically relevant approach to addressing these multifactorial disturbances. Medicinal plants such as *Trigonella foenum-graecum*, *Vitex agnus-castus*, *Withania somnifera*, *Asparagus racemosus*, *Cimicifuga racemosa*, and *Tribulus terrestris* demonstrate significant therapeutic potential through insulin sensitization, hormonal modulation, anti-androgenic activity, antioxidative protection, and restoration of ovulatory function.

Accumulating preclinical and clinical evidence indicates that herbal interventions can improve menstrual regularity, ovulation rates, metabolic profiles, and fertility outcomes, particularly when used as adjuncts to conventional therapies such as metformin, clomiphene citrate, and letrozole. The multi-targeted and systems-level actions of phytochemicals distinguish herbal medicine from single-target pharmacotherapy and support its role in integrative reproductive health management.

However, the successful clinical translation of herbal therapeutics requires rigorous standardization, well-designed multicenter randomized controlled trials, and biomarker-driven outcome assessment. Advances in formulation science, including nanotechnology-assisted delivery systems, along with systems biology and network pharmacology approaches, are expected to enhance bioavailability, reproducibility, and mechanistic clarity.

In conclusion, evidence-based phytotherapy represents a promising, safe, and patient-centered strategy for the long-term management of PCOS and infertility. With strengthened scientific validation and regulatory integration, herbal medicine has the potential to become an important component of personalized and integrative reproductive healthcare.

Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this review article.

Ethical Statement

This review article is based exclusively on previously published studies. No human participants or animals were directly involved; therefore, ethical approval was not required.

Acknowledgement

The authors would like to express their sincere gratitude to **KCT's Krishna College of Pharmacy, Malkapur, Maharashtra, India**, for providing the necessary academic support and resources to carry out this review work. The authors also acknowledge the contributions of researchers and scholars whose published studies formed the basis of this evidence-based review. No external funding was received for the preparation of this manuscript.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers. *CA Cancer J Clin.* 2021;71(3):209–249. doi:10.3322/caac.21660
2. Sirmans SM, Pate KA. Epidemi see, diagnosis, and management of polycystic ovary syndrome. *Front Endocrinol (Lausanne).* 2023;14:112420. doi:10.3389/fendo.2023.112420
3. Zhang Y, Liu Y, Xue J, et al. Metabolic and endocrine features of polycystic ovary syndrome. *Reprod Biol Endocrinol.* 2024;22(1):19. doi:10.1186/s12958-024-01119-4
4. Rasool S, Naikoo NA, Hassan UI, et al. Hormonal dysregulation and infertility in PCOS. *J Endocrinol Invest.* 2022;45(6):1345–1357. doi:10.1007/s40618-021-01671-4
5. Homburg R. Clomiphene citrate—end of an era? A mini-review. *Hum Reprod Update.* 2022;28(5):857–874. doi:10.1093/humupd/dmac025
6. Chaudhary A, Patel R, Shah D. Psychosocial burden and therapeutic challenges in PCOS-related infertility. *Int J Gynaecol Obstet.* 2023;162(2):349–359. doi:10.1002/ijgo.14632
7. Kalra B, Kalra S, Gupta Y. Phytotherapy in endocrine disorders: mechanistic insights and clinical relevance. *Front Pharmacol.* 2024;15:131045. doi:10.3389/fphar.2024.131045
8. Thakur A, Choudhary M, Sharma R, et al. Fenugreek seed extract improves insulin resistance and ovulatory function in PCOS. *J Ethnopharmacol.* 2023;306:116304. doi:10.1016/j.jep.2023.116304
9. Liu C, Wang Y, Li Q, et al. Vitex agnus-castus in female reproductive disorders: clinical and mechanistic evidence. *Phytomedicine.* 2022;98:153981. doi:10.1016/j.phymed.2022.153981
10. Choudhary S, Sharma R, Gupta A. Adaptogenic role of Withania somnifera in reproductive endocrinology. *Reprod Biol.* 2024;32:103578. doi:10.1016/j.repbio.2024.103578
11. Zhao L, Liu M, Zheng S, et al. Berberine and steroidogenic enzyme inhibition: implications for hyperandrogenism. *Bioorg Chem.* 2023;138:106726. doi:10.1016/j.bioorg.2023.106726
12. Patel R, Mehta A, Joshi D. Evidence-based evaluation of Ayurvedic herbs in PCOS. *J Ayurveda Integr Med.* 2022;13(4):100580. doi:10.1016/j.jaim.2022.100580
13. Gupta M, Verma S, Singh P. Black cohosh as an adjunct in ovulation induction: clinical outcomes and safety. *Integr Med Res.* 2024;13(2):100238. doi:10.1016/j.imr.2024.100238
14. Naderi T, Sadeghi R, Mohammadi S. Herbal–pharmaceutical synergy in infertility treatment. *Phytomedicine.* 2023;114:154765. doi:10.1016/j.phymed.2023.154765
15. Sadeghi M, Moradi S, Azadi H. Cinnamon supplementation and metabolic regulation in PCOS. *Nutrients.* 2022;14(11):2243. doi:10.3390/nu14112243
16. Singh R, Verma N, Kaur H. Asparagus racemosus in female infertility: mechanistic and clinical perspectives. *Front Pharmacol.* 2024;15:130219. doi:10.3389/fphar.2024.130219
17. Al-Khazraji SM, Al-Tawaha ARM, Sivanesan I. Phytotherapeutic modulation of reproductive health. *Phytother Res.* 2022;36(5):2281–2294. doi:10.1002/ptr.7435

18. Nair S, Menon R, Joseph J. Spearmint and androgen modulation in women with PCOS. *J Ayurveda Integr Med.* 2023;14(3):101015. doi:10.1016/j.jaim.2023.101015
19. Das P, Ghosh S, Mukherjee A. Tribulus terrestris in ovulation induction and fertility enhancement. *J Reprod Infertil.* 2023;24(4):217–229.
20. Krawg B, Patel S, Mehta K. Curcumin and oxidative stress modulation in ovarian dysfunction. *Front Pharmacol.* 2024;19:145221. doi:10.3389/fphar.2024.145221
21. Sharma R, Verma A, Singh P. Antioxidant phytochemicals in reproductive medicine. *Phytother Res.* 2023;37(12):6781–6792. doi:10.1002/ptr.7951
22. World Health Organization. *WHO Global Report on Traditional and Complementary Medicine*. Geneva: WHO; 2023.
23. Tandon V, Gupta S, Sharma P. Biomarker-based assessment of herbal therapy in PCOS. *Clin Exp Reprod Med.* 2023;50(1):11–19. doi:10.5653/cerm.2023.05001
24. Rasool L, et al. Inflammatory mediators and ovarian dysfunction in PCOS. *Front Endocrinol (Lausanne).* 2023;14:114982. doi:10.3389/fendo.2023.114982
25. Choudhary M, Thakur A, Kalra S. Integrative reproductive medicine: future perspectives. *Front Pharmacol.* 2024;15:132411. doi:10.3389/fphar.2024.132411
26. Arentz S, Smith CA, Abbott J, Bensoussan A. Herbal medicine for polycystic ovary syndrome: a systematic review and meta-analysis. **BMC Complement Med Ther.** 2022;22:78. doi:10.1186/s12906-022-03521-8
27. Mirmohammadi SJ, Hosseini R, Zare M, et al. Effects of herbal medicine on hormonal and metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial. **Phytother Res.** 2022;36(9):3652–3662. doi:10.1002/ptr.7564
28. Zhang Y, Li X, Zhou L, Wang H, Chen J. Efficacy and safety of herbal medicine for female infertility: a systematic review and meta-analysis. **Complement Ther Med.** 2023;68:102844. doi:10.1016/j.ctim.2023.102844

How to cite this article:
Akshay Rajendra Kundale et al. Ijppr.Human, 2026; Vol. 32 (2): 84-97.

Conflict of Interest Statement: All authors have nothing else to disclose.